/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR
DISSEMINATION IN THE UNITED STATES/
MONTREAL, Sept. 18 /CNW Telbec/ - Ranaz Corporation (TSXV: RNZ), ("Ranaz"
or the "Corporation") announced today that it will enter into an agency
agreement (the "Agency Agreement") with Loewen, Ondaatje, McCutcheon Limited,
as lead agent, and Blackmont Capital Inc. in respect of the offering of units
contemplated by the preliminary short form prospectus filed on September 5,
2007 (the "Units"; the "Offering"). Under the terms of the Agency Agreement,
the agents will offer up to 3,846,154 Units at a price of $1.30 per Unit. Each
Unit will consist of one common share (a "Common Share") and one-half of a
warrant of the Corporation. Each whole warrant will entitle its holder, upon
payment of an exercise price of $1.65, to acquire one Common Share within the
24-month period following the closing of the Offering. The agents have been
granted an over-allotment option for a period of 30 days following the closing
of the Offering to arrange for the sale of up to an additional 576,923 Units
at the issue price.
Ranaz anticipates filing a final prospectus on September 19, 2007.
Closing is currently expected to occur on or about September 26, 2007. Ranaz
expects to use the proceeds of the Offering for corporate development and
general working capital purposes. The Offering is subject to regulatory
approval including approval of the TSX Venture Exchange.
The securities being offered have not been and will not be registered
under the U.S. Securities Act of 1933 or any State securities legislation of
the United States. They may not be offered, sold or delivered in the United
States except as part of transactions that are exempt from the registration
requirements of the U.S. Securities Act. The term "United States" has the
meaning ascribed to it in Regulation S promulgated under the U.S. Securities
Act. This release does not constitute an offer for sale of securities in the
About Ranaz Corporation
Ranaz is a corporation specializing in the manufacture and marketing of
protein and dietary supplements in relation to weight loss and obesity
treatments. Its mission is to design, develop and market nutritional, protein
and dietary supplements under its own corporate brands, such as Protidiet and
ProtiLife, as well as under private labels. Ranaz shares have traded under the
symbol RNZ on the TSX Venture Exchange since December 29, 2006.
Certain statements contained in this news release, other than statements
of fact that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown, many of which are beyond Ranaz's control.
Such risks include but are not limited to: the impact of general economic
conditions, changes in the regulatory environment in the jurisdictions in
which Ranaz does business, stock markets volatility, fluctuations in costs,
and changes to the competitive environment due to consolidation, as well as
other risks disclosed in public filings of Ranaz. Consequently, actual future
results may differ materially from the anticipated results expressed in the
forward-looking statements. The reader should not place undue reliance, if
any, on the forward-looking statements included in this news release. These
statements speak only as of the date made and Ranaz is under no obligation and
disavows any intention to update or revise such statements as a result of any
event, circumstances or otherwise.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.
For further information:
For further information: Martin Vidal, Executive Vice President, Ranaz
Corporation, (450) 491-7106, Ext. 213, email@example.com; Jean
Walter, Vice President, MaisonBrison, (514) 731-0000, Ext. 223,